| LUDWIG, Heinz, Zdeněk ADAM, Roman HÁJEK, Richard GREIL, Elena TOTHOVÁ, Felix KEIL, Eva Maria AUTZINGER, Josef THALER, Heinz GISSLINGER, Alois LANG, Miklós EGYED, Irene WOMASTEK a Niklas ZOJER. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. USA: American Society of Clinical Oncology, 2010, roč. 28, č. 30, s. 4635-4641. ISSN 0732-183X. |
Další formáty:
BibTeX
LaTeX
RIS
@article{908628,
author = {Ludwig, Heinz and Adam, Zdeněk and Hájek, Roman and Greil, Richard and Tothová, Elena and Keil, Felix and Autzinger, Eva Maria and Thaler, Josef and Gisslinger, Heinz and Lang, Alois and Egyed, Miklós and Womastek, Irene and Zojer, Niklas},
article_location = {USA},
article_number = {30},
keywords = {multiple myeloma; renal failure},
language = {eng},
issn = {0732-183X},
journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
title = {Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study},
volume = {28},
year = {2010}
}
TY - JOUR
ID - 908628
AU - Ludwig, Heinz - Adam, Zdeněk - Hájek, Roman - Greil, Richard - Tothová, Elena - Keil, Felix - Autzinger, Eva Maria - Thaler, Josef - Gisslinger, Heinz - Lang, Alois - Egyed, Miklós - Womastek, Irene - Zojer, Niklas
PY - 2010
TI - Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study
JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
VL - 28
IS - 30
SP - 4635-4641
EP - 4635-4641
PB - American Society of Clinical Oncology
SN - 0732183X
KW - multiple myeloma
KW - renal failure
N2 - By intent-to-treat analysis a myeloma response was obtained in 72% of 18 previously and 50 not previously treated patients (complete response [CR]/near CR [nCR], 38%; very good partial response [VGPR], 15%; partial response [PR], 13%; minor response [MR], 6%). Renal response was achieved in 62% of patients (renal CR, 31%; renal PR, 7%; renal MR, 24%). Median GFR increased from 20.5 to 48.4 mL/min. GFR improvement correlated with tumor response; the greatest increase to 59.6 mL/min was seen in the group of patients with CR/nCR/VGPR. Median progression-free survival was 12.1 months. One- and 2-year survival rates were 72% and 58%, respectively. Survival did not differ between patients with and without renal response but was inferior in previously treated patients (P < .001). BDD induced a high rate of myeloma and renal responses, and treatment was well tolerated.
ER -
LUDWIG, Heinz, Zdeněk ADAM, Roman HÁJEK, Richard GREIL, Elena TOTHOVÁ, Felix KEIL, Eva Maria AUTZINGER, Josef THALER, Heinz GISSLINGER, Alois LANG, Miklós EGYED, Irene WOMASTEK a Niklas ZOJER. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. \textit{Journal of clinical oncology : official journal of the American Society of Clinical Oncology}. USA: American Society of Clinical Oncology, 2010, roč.~28, č.~30, s.~4635-4641. ISSN~0732-183X.
|
